Merck removed rofecoxib (Vioxx®) from the market early last fall because of reports of an increased number of heart attacks among users. This drug had been widely used for painful arthritis. For this “forthright” action, Merck initially received some adulation. On November 19, 2004, however, The Wall Street Journal published e-mails from Merck’s corporate files [...]

The future looks bright for individuals living with chronic hepatitis B. Only a decade ago there were no treatment options. Although there is still no complete cure for hepatitis B, there are 7 approved drugs for adults (2 for children) and many promising new drugs in development. Current treatments seem to be most effective in [...]